Correction: A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma (Oncotarget (2015) 6 (185-195) DOI: 10.18632/oncotarget.2688);A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma

Oncotarget

Volumn 6, Issue 1, 2015, Pages 185-195

  Zhu, Jingyu ^a,b   Wang, Man ^a,b   Yu, Yang ^a   Qi, Huixin ^a   Han, Kunkun ^a,b   Tang, Juan ^a,b   Zhang, Zubin ^a,b   Zeng, Yuanying ^a,b   Cao, Biyin ^a,b   Qiao, Chunhua ^a   Zhang, Hongjian ^a   Hou, Tingjun ^a,c   Mao, Xinliang ^a,b  

^a SOOCHOW UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

C98; Multiple myeloma; Phosphatidylinositol 3 kinase; Virtual screen

Indexed keywords

ADENOSINE TRIPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK C 98; PROTEIN KINASE P60; SOMATOMEDIN C RECEPTOR; STAT3 PROTEIN; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FURAN DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PIK-C98; PROTEIN KINASE INHIBITOR; THIOCARBAMIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL FREE SYSTEM; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG PENETRATION; DRUG POTENTIATION; DRUG SCREENING; DRUG SPECIFICITY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYDROGEN BOND; MAXIMUM PLASMA CONCENTRATION; MOLECULAR DOCKING; MOUSE; MULTIPLE MYELOMA; NONHUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; MOLECULAR DYNAMICS; NUDE MOUSE; ORAL DRUG ADMINISTRATION; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FURANS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROGEN BONDING; MICE; MICE, NUDE; MICE, SCID; MOLECULAR DYNAMICS SIMULATION; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; THIOCARBAMATES;

EID: 84921415815     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.27350     Document Type: Erratum

References (36)

1. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol. 2011; 6:249-274.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63:11-30.
3. Amzel LM, Huang CH, Mandelker D, Lengauer C, Gabelli SB, Vogelstein B. Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer. 2008; 8:665-669.
4. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004; 30:193-204.
5. Edgar KA, Crocker L, Cheng E, Wagle MC, Wongchenko M, Yan Y, Wilson TR, Dompe N, Neve RM, Belvin M, et al. Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition. Genes Cancer. 2014; 5:113-126.
6. Kim KW, Myers CJ, Jung DK, Lu B. NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/ mTOR pathway in cisplatin-resistant non-small cell lung carcinoma. Genes Cancer. 2014; 5:293-302.
7. Kyle RA. Prognostic factors in multiple myeloma. Stem Cells. 1995; 13:56-63.
8. Qiang YW, Yao L, Tosato G, Rudikoff S. Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. Blood. 2004; 103:301-308.
9. Chang H, Qi XY, Claudio J, Zhuang L, Patterson B, Stewart AK. Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res. 2006; 30:262-265.
10. Zhu J, Wang M, Cao B, Hou T, Mao X. Targeting the phosphatidylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma. Curr Med Chem. 2014; 21:3173-3187.
11. Martelli AM, Evangelisti C, Chappell W, Abrams SL, Basecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/ mTOR pathway. Leukemia. 2011; 25:1064-1079.
12. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370:997-1007.
13. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014; 370:1008-1018.
14. Han K, Xu X, Chen G, Zeng Y, Zhu J, Du X, Zhang Z, Cao B, Liu Z, Mao X. Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization. J Hematol Oncol. 2014; 7:9doi: 10.1186/1756-8722-7-9.
15. Mao X, Cao B, Wood TE, Hurren R, Tong J, Wang X, Wang W, Li J, Jin Y, Sun W, et al. A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway. Blood. 2011; 117:1986-1997.
16. Tang J, Zhu J, Yu Y, Zhang Z, Chen G, Zhou X, Qiao C, Hou T, Mao X. A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo. Oncotarget. 2014; 5:3836-3848.
17. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res. 2000; 28:235-242.
18. SYBYL 8.1 Tripos, Inc, St. Louis, MO. USA 2010
19. Zhu J, Pan P, Li Y, Wang M, Li D, Cao B, Mao X, Hou T. Theoretical studies on beta and delta isoformspecific binding mechanisms of phosphoinositide 3-kinase inhibitors. Mol Biosyst. 2014; 10:454-466.
20. Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys. 1977; 23:327-341.
21. Cao B, Li J, Zhu J, Shen M, Han K, Zhang Z, Yu Y, Wang Y, Wu D, Chen S, et al. The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity. J Biol Chem. 2013; 288:34181-34189.
22. Li J, Cao B, Zhou S, Zhu J, Zhang Z, Hou T, Mao X. Cyproheptadine-induced myeloma cell apoptosis is associated with inhibition of the PI3K/AKT signaling. Eur J Haematol. 2013; 91:514-521.
23. Ling C, Chen G, Chen G, Zhang Z, Cao B, Han K, Yin J, Chu A, Zhao Y, Mao X. A deuterated analog of dasatinib disrupts cell cycle progression and displays anti-non-small cell lung cancer activity in vitro and in vivo. Int J Cancer. 2012; 131:2411-2419.
24. Dong J, Liu S, Zhang H, Hua Q, Zhao X, Miao L. Determination of naloxone-3-glucuronide in human plasma and urine by HILIC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2013; 942-943:83-87.
25. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, Williams RL. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell. 2000; 6:909-919.
26. Pomel V, Klicic J, Covini D, Church DD, Shaw JP, Roulin K, Burgat-Charvillon F, Valognes D, Camps M, Chabert C, et al. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J Med Chem. 2006; 49:3857-3871.
27. Verhoven B, Schlegel RA, Williamson P. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. J Exp Med. 1995; 182:1597-1601.
28. Mao X, Stewart AK, Hurren R, Datti A, Zhu X, Zhu Y, Shi C, Lee K, Tiedemann R, Eberhard Y, et al. A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood. 2007; 110:4047-4054.
29. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008; 7: 1851-1863.
30. Crabbe T. Exploring the potential of PI3K inhibitors for inflammation and cancer. Biochem Soc Trans. 2007; 35:253-256.
31. Giuliano KA, Haskins JR, Taylor DL. Advances in high content screening for drug discovery. Assay Drug Dev Tech. 2003; 1:565-577.
32. Frederick R, Mawson C, Kendall JD, Chaussade C, Rewcastle GW, Shepherd PR, Denny WA. Phosphoinositide-3-kinase (PI3K) inhibitors: identification of new scaffolds using virtual screening. Bioorg Med Chem Lett. 2009; 19:5842-5847.
33. Hou TJ, Xu XJ. Recent development and application of virtual screening in drug discovery: An overview. Curr Pharm Des. 2004; 10:1011-1033.
34. Pinson JA, Schmidt-Kittler O, Zhu J, Jennings IG, Kinzler KW, Vogelstein B, Chalmers DK, Thompson PE. Thiazolidinedione-based PI3Kalpha inhibitors: an analysis of biochemical and virtual screening methods. Chem Med Chem. 2011; 6:514-522.
35. Zhang J, Choi Y, Mavromatis B, Lichtenstein A, Li W. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway. Oncogene. 2003; 22:6289-6295.
36. Shi M, Zhou X, Zhang Z, Wang M, Chen G, Han K, Cao B, Liu Z, Mao X. A novel PI3K inhibitor displays potent preclinical activity against an androgenindependent and PTEN-deficient prostate cancer model established from the cell line PC3. Toxicol Lett 2014; 228:133-139.